



New Antibiotic Compounds: Discovery and Strategies

Guest Editors:

Dr. Florie Desriac

CBSA, Bacterial Communication
and Antimicrobial Strategies,
University of Caen Normandie,
Caen, France

Dr. Yannick Fleury

LBCM, Laboratoire de
Biotechnologie et Chimie
Marines Université de Brest,
Quimper, France

Deadline for manuscript
submissions:

closed (31 May 2023)

Message from the Guest Editors

This Special Issue welcomes all submissions related to antibacterial discovery. Perspectives (opinion letters) and submissions focusing on requirements to improve/accelerate antibacterial screening and hit to lead translation are encouraged.

Potential topics include but are not limited to the following:

- Natural or synthetic antibacterial compounds;
- Antibiotic potentiators, efflux pumps inhibitors;
- Antivirulence, antibiofilm, and/or quorum quenchers;
- Microbial genome mining for antibiotic discovery;
- New strategies to enhance high throughput screening (from natural or synthetic libraries);
- Natural products dereplication strategies;
- Antibiotic discovery platforms.

Keywords: antibiotic; antimicrobial; discovery; high-throughput; screen; molecule-based strategies





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPUS / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1
(*General Pharmacology, Toxicology and Pharmaceutics*)

Contact Us

Antibiotics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)